Baker IDI Heart and Diabetes Institute, Melbourne, Australia.
Diab Vasc Dis Res. 2011 Oct;8(4):303-4. doi: 10.1177/1479164111421034.
Nrf-2 (NF-E2-related factor 2) is a regulator of anti-oxidant, anti-inflammatory and detoxification pathways. Coordinated augmentation of these key defence pathways via Nrf-2 signalling is being investigated for the treatment of chronic diseases, including diabetes and its complications. The first to reach commercial development is the triterpenoid, bardoxolone methyl. In recent clinical trial, bardoxolone rapidly improved kidney function on average by 5-10 ml/min within 4 weeks of therapy. Importantly, this improvement was sustained during one year of active treatment. This suggests that rather that overworking a failing system, bardoxolone appeared to safely augment renal function, at least to one year. If similar improvements in kidney function can be reproduced in the upcoming BEACON trial, it will represent a major advance on conventional therapy and new way to bring balance to the failing kidney.
Nrf-2（NF-E2 相关因子 2）是抗氧化、抗炎和解毒途径的调节剂。通过 Nrf-2 信号传导协调这些关键防御途径的增强，正在被研究用于治疗慢性疾病，包括糖尿病及其并发症。第一个达到商业开发的是三萜类化合物 bardoxolone 甲基。在最近的临床试验中，bardoxolone 在 4 周的治疗内平均使肾功能提高了 5-10ml/min。重要的是，这种改善在一年的积极治疗期间得以维持。这表明 bardoxolone 似乎并没有使衰竭的系统过度工作，而是安全地增强了肾功能，至少在一年的时间内是这样。如果即将进行的 BEACON 试验能够复制类似的肾功能改善，这将代表对传统治疗方法的重大进展，也是为衰竭的肾脏恢复平衡带来的新方法。
